Marketing in Pharmaceutical Industry Flashcards

1
Q

What is the role of governance in a pharmaceutical company?

A
  • Determines objectives of organisation
  • Defines ethics, culture, and governance framework
  • Ensures compliance with regulatory, statutory and legal obligations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the main functions of management in a pharmaceutical company?

A
  • Delivers the objectives of organisation
  • Works within the ethical and cultural framework
  • Provides assurance to the governing body
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

List the core functions typically found in pharmaceutical companies.

A
  • Research and Development
  • Manufacturing
  • Drug Supply/Distribution
  • Commercialisation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the typical divisions within pharmaceutical companies?

A
  • Core Functions
  • Support Functions (e.g., Finance, Human resources, External affairs & communications, Investor relations)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the purpose of commercial input in drug development?

A
  • Target Selection and Target Product Profile (TPP)
  • Commercial valuations
  • Competitor intelligence
  • Sales projections
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Fill in the blank: The maximum R&D investment occurs during the _______ phase.

A

pre-launch

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the role of NICE in relation to new medicines?

A

Conducts Health Technology Appraisals (HTAs) to recommend or not recommend medicines for use within NHS England

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Define Quality Adjusted Life Year.

A

A measure of the state of health of a person or group in which the benefits, in terms of length of life, are adjusted to reflect the quality of life.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the components of a SWOT analysis?

A
  • Strengths
  • Weaknesses
  • Opportunities
  • Threats
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

List the strategic imperatives in marketing.

A
  • Small number (3-6) of ‘most important’ priorities
  • Derived from the situational analysis
  • ‘What we want to achieve’
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are typical marketing tactics during the launch phase?

A
  • Secure national level funding
  • Insight gathering
  • Develop key messages
  • Identify opportunities to incorporate new treatment into guidelines
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the role of the Medical Department in pharmaceutical companies?

A
  • Identify new information about hazards associated with a medicine
  • Collect and collate details of adverse events
  • Assess the impact of new safety data on the drug
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the purpose of evidence generation in pharmaceutical marketing?

A

To generate robust ‘real world evidence’ to address clinically-important data gaps. But it may not truly reflect the real world.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Fill in the blank: The Market Access Department advocates for funding by health authorities such as _______.

A

the NHS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the NICE threshold for cost per QALY gained?

A

£30,000 per QALY gained

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What factors are considered in the measurement of effectiveness for NICE assessments?

A

Quality Adjusted Life Year (QALY) and specific monitoring requirements

17
Q

List the types of study used in evidence generation.

A
  • Interventional studies
  • Observational studies
  • Prospective and retrospective data collection
18
Q

What is the significance of the utility score in QALY calculations?

A

It reflects a patient’s quality of life on a scale from 0 to 1.

19
Q

What is the role of the Market Access Department in local access?

A
  • Overcome local barriers restricting use of NICE approved drugs
  • Negotiate local commercial contracts
20
Q

What does pharmacovigilance involve?

A
  • Identify new hazards associated with a medicine
  • Collect adverse events
  • Assess safety data
21
Q

What quality of life measures does NICE prefer?

A

Generic quality of life measures (EQ5D, SF-36)

22
Q

What does NICE not consider when evaluating costs?

A

Positive impact on wider societal costs

23
Q

What is a challenge for expensive one-off therapies?

A

Full cost paid upfront with benefits accruing over many years

24
Q

What does the NHS expect regarding pricing for treatments?

A

A single price for a treatment, regardless of indication

25
Q

What are the key responsibilities of the MHRA?

A

Ensuring safety, quality, and efficacy of medicines, medical devices, and blood components

26
Q

What mechanism does the MHRA use to achieve its responsibilities?

A

Approval of clinical trials and granting of Marketing Authorisation

27
Q

What legal framework was introduced by the Medicines Act, 1968?

A

A licensing and governance system for medicines

28
Q

What does the ABPI Code of Practice set standards for?

A

Company behaviour in pharmaceutical sales and interactions with healthcare professionals

29
Q

What must promotion of prescription-only medicines to healthcare providers be?

A

Evidence-based, balanced, not misleading, and consistent with approved SPC

30
Q

Is direct-to-consumer promotion allowed for prescription-only medicines in the UK?

31
Q

What is allowed in disease awareness promotion?

A

Promotion is allowed for over-the-counter (OTC) products

32
Q

What are the principles outlined in the ABPI Code of Practice?

A
  • Benefitting patients
  • Acting with integrity
  • Promoting transparency
  • Treating everyone with respect